- AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms
- Proceeds of the financing will be used to advance a portfolio of programmes and take the lead molecule into clinical trials
- The syndicate, led by the Novartis Venture Fund, also includes MPM Capital, Brandon Capital, EQT Life Sciences, Bristol Myers Squibb and current insider the Dementia Discovery Fund
Read more…
https://www.optimumcomms.com/wp-content/uploads/2023/10/Template_Logo_300x180px-80x80Web_Logos-5.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-09 08:14:042023-10-09 09:22:49AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease